Harvey I. Pass, MD

  • Specialty: Thoracic Surgery
  • Language: English
  • Phone: 212-731-5414

About Me


Conditions and Treatments

thoracic surgery, esophageal disorders, mesothelioma, lung metastasis, tumor of mediastinum, lung cancer, cancer surgery, esophageal cancer, minimally invasive surgery


  • Stephen E. Banner Professor of Thoracic Oncology, Department of Cardiothoracic Surgery
  • Professor, Department of Surgery
  • Chief Thoracic Oncology NYU Can Center
  • Vice Chair Research NYUHC
  • Stephen E Banner Prof Thoracic Onc
  • Chief Div Thor Surg NYULMC
Board Certifications
  • American Board of Thoracic Surgery - Thoracic Surgery, 1983
Education and Training
  • Fellowship, National Institute of Health, Cardio-Thoracic Surg, 1986
  • Residency, Medical Univ. of South Carolina, Cardio-Thoracic Surg, 1982
  • Residency, University of Mississippi, Surgery, 1980
  • MD from Duke University, 1973

Locations and Appointments

61 Insurance Plans Accepted
  • Aetna HMO
  • Aetna Indemnity
  • Aetna Medicare
  • Aetna POS
  • Aetna PPO/EPO
  • Affinity
  • Affinity Exchange- Essential
  • Cigna EPO/POS
  • Cigna PPO
  • ElderPlan
  • Empire Blue Cross Blue Shield EPO
  • Empire Blue Cross Blue Shield HMO
  • Empire Blue Cross Blue Shield Indemnity
  • Empire Blue Cross Blue Shield MediBlue
  • Empire Blue Cross Blue Shield POS
  • Empire Blue Cross Blue Shield PPO
  • Empire Blue Cross Blue Shield Pathways, Enhanced
  • Fidelis Child Health
  • Fidelis Exchange
  • Fidelis Family Health
  • Fidelis Medicaid
  • Fidelis Medicare
  • HIP Access I
  • HIP Access II
  • HIP Child Health
  • HIP Medicare
  • HealthRepublic
  • HealthSmart (WTC)
  • Healthfirst
  • Humana Medicare
  • Local 1199 PPO
  • MagnaCare PPO
  • Medicare
  • MultiPlan/PHCS PPO
  • NJ Medicaid
  • NY Medicaid
  • NYS Empire Plan
  • Oscar
  • Oxford Exchange
  • Oxford Freedom
  • Oxford Liberty
  • Oxford Medicare
  • Railroad Medicare
  • Tricare
  • United Exchange- Compass
  • UnitedHealthcare Community & State Plan
  • UnitedHealthcare EPO
  • UnitedHealthcare HMO
  • UnitedHealthcare Medicare
  • UnitedHealthcare POS
  • UnitedHealthcare PPO
  • UnitedHealthcare Top Tier
  • Visiting Nurse Service (VNS) Medicare
  • WellCare Child Health
  • WellCare Family Health
  • WellCare Medicaid
  • WellCare Medicare
*Insurance listed above may not be accepted at all office locations. Please confirm prior to each visit. The information presented here may not be complete or may have been changed.
NYU Cardiothoracic Surgery Associates

160 East 34th Street, 8th Floor
New York, NY 10016


Phone: 212-731-5414

Welcome back!

As a returning patient for this doctor, please schedule an appointment using your MyChart at NYU Langone account.

Learn more about MyChart at NYU Langone.

My Research

The Thoracic Oncology laboratory investigates biomarker signatures for lung cancer and mesothelioma both in tissue and in the blood for discovery and validation. This work is supported by the National Cancer Institute Early Detection Research Network since 2005. Specifically our interests include the use of plasma osteopontin for the early detection and diagnosis of lung cancer, and studies of the role of osteopontin isoforms in order to increase specificity. Osteopontin is also being investigated for the prognosis of early lung cancer and mesothelioma, and we have demonstrated that plasma osteopontin can stratify resected Stage I lung cancers by their disease free survival. In mesothelioma, modeling of clinical parameters with plasma osteopontin can predict which patients will have long term survival. Other mesothelioma biomarkers include Fibulin 3 which to date has the highest sensitivity and specificty published for the diagnosis of mesothelioma using blood based biomarkers. Fibulin 3 levels in blood as well as in pleural effusions can differentiate mesothelioma from individuals with benign effusions, from others with non mesothelioma malignant effusions, and from patients exposed to asbestos but who do not have mesothelioma. A large validation study using an asbestos exposed cohort of individuals in Santiago Chile funded by the NCI will commence in the third quarter of 2015.  MicroRNA studies, using NanoString are also the subject of an NCI awarded RO1 to Drs. Pass and Carlo Croce for the differential diagnosis of the solitary pulmonary nodule, and these studies are ongoing. The Thoracic Oncology Laboratory collaborates with Industry for the discovery and validation of biomarkers. Biomarker profiles for lung cancer and mesothelioma using  Slow Off Rate Modified Aptamers (SOMAmers) in collaboration with Somalogic, Boulder CO, have been published and are in final validation phases. Other proteomic based plasma biomarker studies for lung cancer have been reported in collaboration with Integrated Diagnostics.


  • Blood-based lung cancer biomarkers identified through proteomic discovery in cancer tissues, cell lines and conditioned medium

    Birse, Charles E; Lagier, Robert J; FitzHugh, William; Pass, Harvey I; Rom, William N; Edell, Eric S; Bungum, Aaron O; Maldonado, Fabien; Jett, James R; Mesri, Mehdi; Sult, Erin; Joseloff, Elizabeth; Li, Aiqun; Heidbrink, Jenny; Dhariwal, Gulshan; Danis, Chad; Tomic, Jennifer L; Bruce, Robert J; Moore, Paul A; He, Tao; Lewis, Marcia E; Ruben, Steve M
    Clinical proteomics. 2015. 12 (1): 18-18

  • Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies

    Bononi, Angela; Napolitano, Andrea; Pass, Harvey I; Yang, Haining; Carbone, Michele
    Expert review of respiratory medicine. 2015 Oct. 9 (5): 633-654

  • A STAT3-NFkB/DDIT3/CEBPbeta axis modulates ALDH1A3 expression in chemoresistant cell subpopulations

    Canino, Claudia; Luo, YuYing; Marcato, Paola; Blandino, Giovanni; Pass, Harvey I; Cioce, Mario
    Oncotarget. 2015 Mar. 6 (14): 12637-12653

Read All Publications (525)